Sienna Biopharmaceuticals Inc. of California, a privately held medical dermatology and aesthetics company, has acquired Creabilis SA (more recently a PLC), for an undisclosed upfront payment in cash and stock, as well as additional payments dependent on achieving specific regulatory and commercial milestones, which could exceed $150m.
Creabilis has been ready to start Phase III trials for quite some time: initial Phase IIb data were reported in...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
